Drug intelligence / Profile preview

apomorphine + clonidine + dexamethasone + protirelin

Development stage
Unknown
Lead developer
Britannia Pharmaceuticals
Modality
Peptides, Small Molecules
Administration
Subcutaneous, Sublingual, Oral, Transdermal, Epidural, Intravenous, Intramuscular, Ophthalmic
01

Overview

This is a combination of four pharmacologically active agents, each with distinct mechanisms and clinical uses: - **Apomorphine** is a non-ergoline dopamine agonist primarily used for the acute, intermittent treatment of hypomobility and "off" episodes in advanced Parkinson's disease. It acts mainly by stimulating dopamine D2, D3, and D5 receptors in the brain regions involved in motor control[1]. - **Clonidine** is an alpha-2 adrenergic receptor agonist indicated for hypertension, severe cancer pain (with opiates), ADHD (as monotherapy or adjunct), withdrawal syndromes, and as a diagnostic agent for pheochromocytoma. It reduces sympathetic outflow from the CNS by stimulating alpha-2 adrenoceptors[5]. - **Dexamethasone** is a potent synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressant properties. It acts via binding to the glucocorticoid receptor to modulate gene expression. - **Protirelin** (also known as TRH or Thyrel TRH) is a synthetic tripeptide analogue of thyrotropin-releasing hormone used diagnostically to assess pituitary function by stimulating release of thyroid-stimulating hormone (TSH) from the anterior pituitary[6][8][9]. There are no known approved pharmaceutical products combining all four agents into one formulation; this appears to be an investigational or theoretical combination.

02

Targets

ADRA2C (α2C)TRHR (Thyrotropin-releasing hormone receptor)ADRA2A (α2A)ADRA2B (α2B)DRD2 (Dopamine D2 Receptor)GR (Glucocorticoid receptor)DRD3 (Dopamine receptor D3)DRD5 (Dopamine D5 Receptor)

Beyond the preview

Go deeper on apomorphine + clonidine + dexamethasone + protirelin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on apomorphine + clonidine + dexamethasone + protirelin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call